Wall Street Zen Downgrades NeuroPace Stock Rating

Analysts cut the medical device company's rating from "buy" to "hold"

Mar. 15, 2026 at 5:18am

Got story updates? Submit your updates here. ›

Wall Street Zen, an equity research firm, has downgraded NeuroPace (NASDAQ:NPCE) stock from a "buy" rating to a "hold" rating in a new research note. NeuroPace is a medical device company based in Mountain View, California that develops neuromodulation systems for treating neurological disorders, including its flagship product, the RNS System for adults with medically refractory focal epilepsy.

Why it matters

The downgrade from Wall Street Zen could impact investor sentiment and trading activity around NeuroPace stock. As a publicly traded company, analyst ratings and price targets can significantly influence how the stock performs. The change in rating may signal concerns about the company's growth prospects or competitive positioning that investors should be aware of.

The details

In its research note, Wall Street Zen cited several factors for the downgrade, including increased competition in the neuromodulation market and potential challenges with NeuroPace's product pipeline and commercialization efforts. The firm also noted that while NeuroPace has seen some positive momentum, there are still uncertainties around the long-term outlook for the company's core RNS System product.

  • Wall Street Zen issued the downgrade on Sunday, March 14, 2026.

The players

Wall Street Zen

An equity research firm that provides analysis and ratings on publicly traded companies.

NeuroPace

A medical device company based in Mountain View, California that develops neuromodulation systems for treating neurological disorders, including its flagship RNS System product for adults with medically refractory focal epilepsy.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

The downgrade of NeuroPace stock by Wall Street Zen highlights the competitive pressures and uncertainties facing the medical device company as it seeks to grow its business and maintain its position in the neuromodulation market. Investors will be closely watching to see how NeuroPace responds to the analyst's concerns and whether the company can overcome the challenges it faces.